Prevalence of and Risk Factors for Community-Based Osteoporosis and Associated Fractures in Beijing: Study Protocol for a Cross-Sectional and Prospective Study

Abstract

Background: Osteoporosis (OP) patients are usually asymptomatic until osteoporotic fractures occur, which makes early diagnosis and prevention difficult, and the associated fractures secondary to OP could be preventable with appropriate management. Therefore, early identification and relevant evidence-based management of OP could guide the prevention of subsequent fractures. This study will investigate the prevalence of OP and the incidence of osteoporotic fractures in Beijing community residents to further explore the related risk factors and put forward suggestions for people aged 45–80 years old.Methods: Over 2 years, this study will conduct an OP screening and a prospective follow-up in the Beijing community to investigate the incidence of osteoporotic fractures. The study will undertake bone mineral density detection, collect biological samples, and record information via questionnaires.Discussion: The study aims to investigate the potential risk factors for osteoporosis and explore syndromes from traditional Chinese medicine that are associated with this condition based on large samples from the Beijing community. Data on the incidence of osteoporotic fractures among community dwellers in Beijing over the two-years will be available on the Chinese clinical trial registry: ChiCTR-SOC-17013090.

Phosphatidylserine liposomes containing curcumin inhibit bone loss in osteoporotic rats: A possible synergy through a common signaling pathway

“…Clinical and experimental studies demonstrated MP as a common cause of osteoporosis through stimulation of osteoclastogenesis, bone resorption, apoptosis of mature osteoblasts, and osteocytes, resulting in bone loss and fragility (Canalis, 2005; Sun et al, 2020). At the molecular level, MP increases the expression of RANKL, as a membrane‐bound molecule of the tumor necrosis factor ligand family, which is expressed in osteoblasts.…”

“…It was shown that prednisolone administration could damage the structure of the tibia represented by the occurrence of the increasing lacunae, thinning trabeculae, resulting in bone fragility (Canalis, 2005; Sun et al, 2020). The result of this study revealed that MP administration caused a significant decline in bone stiffness which was significantly improved by PSL‐Cur administration which was evaluated using a biomechanical three‐point bending test on the rats' tibia.…”

“…The bone fragility in osteoporosis is due to the degeneration of the microarchitecture of bone tissue and the decrease in mineral density. Long‐term steroid medications, hormonal changes, and insufficient dietary intake are among the most common causes of osteoporosis (Colón‐Emeric & Saag, 2006; Sun et al, 2020). Glucocorticoid (GC) administration promotes osteoclastogenesis, resulting in the suppression of bone formation and the subsequent increased risk of bone fracture.…”

“…Glucocorticoid (GC) administration promotes osteoclastogenesis, resulting in the suppression of bone formation and the subsequent increased risk of bone fracture. It has been confirmed that pharmacological doses of GCs such as methylprednisolone (MP) inhibit different pathways of bone formation such as reduction in osteocalcin production and calcium absorption (Canalis, 2005;Ton et al, 2005).…”

The Potential Role of Serum IGF-1 and Leptin as Biomarkers: Towards Screening for and Diagnosing Postmenopausal Osteoporosis

“…In this community-based cross-sectional and prospective follow-up study, 24 we sought 1055 postmenopausal women who responded to an invitation to participate from Chaoyang District or Fengtai District in Beijing. Then, the participants were screened, based on predetermined inclusion and exclusion criteria.…”